Onco Wiki / drapeau rouge

Exposition in-utéro au diéthylstilbestrol (DES) — préscripteur d'oestrogène non stéroïdien synthétique...

Vue déterministe de l'entité source de la LJAM. L'autorité clinique demeure avec les ID de la source cités et l'état d'approbation de l ́examinateur.

IDRF-REPRODUCTIVE-DES-IN-UTERO-EXPOSURE-PREVENTION
TypeSignal d’alerte
Étatreviewed 2026-05-19 | pending_clinical_signoff
MaladiesDIS-BREAST DIS-CERVICAL DIS-VULVAR-VAGINAL-SCC
SourcesSRC-NCCN-BREAST-2025 SRC-NCCN-CERVICAL-2025 SRC-USPSTF-BREAST-2024

Origine du drapeau rouge

DéfinitionIn-utero exposure to diethylstilbestrol (DES) — synthetic non-steroidal estrogen prescribed 1940-1971 (USA) and 1948-1978 (Europe) to women with prior miscarriage or threatened miscarriage. DES-exposed daughters carry ~40-fold increased risk of clear-cell adenocarcinoma of the vagina and cervix (peak incidence ages 15-30 but cases continue into older ages), ~2-fold lifetime risk of breast cancer (post-menopausal incidence doubles after age ~40), and structural reproductive anomalies (T-shaped uterus, vaginal adenosis, cervical hood). DES-exposed mothers themselves have ~30% increased breast cancer risk. Although the exposed cohort is aging out (most exposures pre-1978), surveillance continues lifelong. Prevention-persona RedFlag (§20 v0.3 reproductive expansion). Cohort still in active surveillance pathway through ~2050 given peak prescription years.
Direction cliniqueenquêter
Catégorieautres

Logique de déclenchement

{
  "any_of": [
    {
      "finding": "des_in_utero_exposure_confirmed",
      "value": true
    },
    {
      "finding": "des_exposed_daughter_per_mother_history",
      "value": true
    },
    {
      "finding": "des_exposed_mother_self_history",
      "value": true
    }
  ],
  "type": "lab_value"
}

Notes

Prevention-persona RedFlag for DES in-utero exposure cohort. Surveillance is intensified relative to general population (annual pelvic with careful vaginal/cervical inspection; colposcopy if abnormal cytology; mammography at younger age threshold per NCCN modifier risk; consider MRI breast screening adjunct given doubled risk). STUB pending two-Co-Lead signoff per CHARTER §6.1 dev-mode.

Utilisé par

Indication